On Tuesday, Creative Medical Technology Holdings Inc (NASDAQ: CELZ) opened lower -11.22% from the last session, before settling in for the closing price of $2.05. Price fluctuations for CELZ have ranged from $1.50 to $6.90 over the past 52 weeks.
A company in the Healthcare sector has jumped its sales by 75.38% annually for the last half of the decade. Company’s average yearly earnings per share was noted 45.01% at the time writing. With a float of $2.55 million, this company’s outstanding shares have now reached $2.58 million.
Creative Medical Technology Holdings Inc (CELZ) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Creative Medical Technology Holdings Inc is 1.37%, while institutional ownership is 2.74%. The most recent insider transaction that took place on Feb 19 ’25, was worth 4,312. In this transaction Director of this company sold 750 shares at a rate of $5.75, taking the stock ownership to the 351 shares. Before that another transaction happened on Feb 18 ’25, when Company’s Director sold 750 for $5.00, making the entire transaction worth $3,750. This insider now owns 1,101 shares in total.
Creative Medical Technology Holdings Inc (CELZ) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -1.12 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.63) by -0.49.
According to the Wall Street analysts, stocks earnings will be around 45.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.61% during the next five years compared to 75.38% growth over the previous five years of trading.
Creative Medical Technology Holdings Inc (NASDAQ: CELZ) Trading Performance Indicators
Check out the current performance indicators for Creative Medical Technology Holdings Inc (CELZ). In the past quarter, the stock posted a quick ratio of 20.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 469.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.91, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.40 in one year’s time.
